Wang Qizhang, Zhou Qin, Zhao Zeliang, Liu Chao, Zheng Jiawei
Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lymphat Res Biol. 2022 Oct;20(5):507-513. doi: 10.1089/lrb.2021.0053. Epub 2022 Jan 17.
Sclerotherapy is the first-line therapeutic method for lymphatic malformations (LMs). This retrospective cohort study evaluated the effectiveness and safety of a novel combined foam sclerosant: polidocanol and pingyangmycin foam (PPF), for treating cervicofacial macrocystic LMs. From July 2018 to October 2020, 51 patients with cervicofacial macrocystic LMs were enrolled in this study. All patients received intralesional 3% polidocanol or PPF injections. The outcome was evaluated regarding demographic and clinical characteristics, degree of treatment response, and post-treatment complications. Overall, 16 patients (31.4%) underwent PPF sclerotherapy. All these patients (100%) showed remarkable reduction in lesion size within three sessions. Excellent responses were shown in 88.5% of these patients within three sessions, which is higher than single polidocanol sclerotherapy (80%). The average sessions (duration) of PPF sclerotherapy were 2.5, which was significantly shorter than the single foam sclerotherapy ( < 0.05). Treatment duration was significantly associated with age, lesion location, lesion size, and number of cysts ( < 0.05). No severe complications were noted in this study. Local or systemic complications, such as swelling and mild fever occurred but subsided without any specific treatment. PPF is a safe, and effective combined foam sclerosant for the treatment of cervicofacial macrocystic LMs. This combined foam can improve treatment response and reduce treatment duration compared with a single sclerosant. It can be broadly used if further large-scale clinical trials verify its efficacy and safety.
硬化治疗是淋巴管畸形（LMs）的一线治疗方法。这项回顾性队列研究评估了一种新型联合泡沫硬化剂：聚多卡醇平阳霉素泡沫（PPF）治疗颈面部大囊型LMs的有效性和安全性。2018年7月至2020年10月，51例颈面部大囊型LMs患者纳入本研究。所有患者均接受病灶内注射3%聚多卡醇或PPF。对患者的人口统计学和临床特征、治疗反应程度及治疗后并发症进行评估。总体而言，16例患者（31.4%）接受了PPF硬化治疗。所有这些患者（100%）在三个疗程内病灶大小均显著缩小。88.5%的患者在三个疗程内显示出良好反应，高于单一聚多卡醇硬化治疗（80%）。PPF硬化治疗的平均疗程（持续时间）为2.5个疗程，显著短于单一泡沫硬化治疗（P<0.05）。治疗持续时间与年龄、病灶位置、病灶大小及囊肿数量显著相关（P<0.05）。本研究未观察到严重并发症。出现了局部或全身并发症，如肿胀和低热，但未经任何特殊治疗即消退。PPF是一种安全有效的联合泡沫硬化剂，可用于治疗颈面部大囊型LMs。与单一硬化剂相比，这种联合泡沫可改善治疗反应并缩短治疗持续时间。如果进一步的大规模临床试验证实其疗效和安全性，其可被广泛应用。
